

VALEANT PHARMACEUTICALS INTERNATIONAL

Form 8-K

August 05, 2004

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): August 5, 2004

Valeant Pharmaceuticals International

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of
incorporation or
organization)

1-11397
(Commission File
Number)

33-0628076
(IRS Employer
Identification No.)

3300 Hyland Avenue
Costa Mesa, California 92626

(Address of principal executive offices) (Zip Code)

(714) 545-0100

(Registrant's telephone number, including area code)

TABLE OF CONTENTS

Item 5. Other Events and Required FD Disclosure.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

Item 12. Results of Operations and Financial Condition.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

Table of Contents

Item 5. Other Events and Required FD Disclosure.

The Company recorded a pre-tax charge of \$16 million (\$10.1 million after taxes) in discontinued operations in the 2004 second quarter for environmental remediation costs associated with a facility that was part of the Company's Biomedicals division divested last year.

Item 7. Financial Statements, *Pro Forma* Financial Information and Exhibits.

(c) Exhibits

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press release dated August 5, 2004.

Item 12. Results of Operations and Financial Condition.

On August 5, 2004, the Company issued a press release announcing a preliminary estimate of results of operations in the second fiscal quarter of 2004 and financial condition at June 30, 2004. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference.

The information in this Item 12, including the exhibit attached hereto, will not be treated as filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, or into another filing under the Exchange Act, unless that filing expressly refers to such information.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 5, 2004

VALEANT PHARMACEUTICALS INTERNATIONAL

By: /s/ Bary G. Bailey
Bary G. Bailey
Executive Vice President and Chief
Financial Officer

-2-

Table of Contents

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press release dated August 5, 2004.